The Asthma Therapeutics Market is expected to register a CAGR of 5.2% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Asthma Therapeutics Market report covers analysis by Product Type (Dry powder inhalers, Metered dose inhalers, Mist inhalers, Nebulizer); Drug Class (Anti-inflammatory drugs, Bronchodilators, Combination therapy); Route of administration (Oral, Inhaled, Intravenous, Subcutaneous), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Asthma Therapeutics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Asthma Therapeutics Market Segmentation
Product Type- Dry powder inhalers
- Metered dose inhalers
- Mist inhalers
- Nebulizer
- Anti-inflammatory drugs
- Bronchodilators
- Combination therapy
- Oral
- Inhaled
- Intravenous
- Subcutaneous
Strategic Insights
Asthma Therapeutics Market Growth Drivers- Increased incidence of asthma: Asthma is a chronic respiratory condition that is increasingly becoming common worldwide, due to urbanization, increased exposure to allergens, pollution, and lifestyle changes. This increase in asthma cases has created a higher demand for medications and treatments to manage the condition. In January 2023, AstraZeneca's Tezspire (tezepelumab) was adopted by CHMP with a positive opinion for self-administration through a prefilled pen for patients diagnosed with severe asthma aged 12 years and older, increasing convenience and flexibility. As more people are diagnosed with asthma, the need for effective therapeutic solutions continues to grow, driving the expansion of the asthma therapeutics market.
- Increasing awareness and early diagnosis: Public health campaigns and awareness programs have increased the knowledge of asthma symptoms, including wheezing, shortness of breath, and coughing. Thus, people take medical advice early on and undergo proper diagnosis and treatment. Early interventions can help prevent severe complications and enhance patient quality of life, making patients increase demands for a variety of asthma management options such as medicines and inhalers.
- Developments in the inhalation equipment: Technological advancements in inhalation devices have made them more efficient and user-friendly. Smart inhalers, for instance, can monitor usage and provide reminders to adhere to treatment regimens. They ensure that the right dose of medication is given to the patient, thereby maximizing the outcome of treatment. In March 2023, Teva Pharmaceuticals collaborated with Rimidi to introduce respiratory patient monitoring with data from the Digihaler System by Teva at Desert Oasis Healthcare in California. The Digihaler is a smart inhaler system that provides objective data for asthma management. Convenience and improved efficacy are the factors that make the modern inhalation device increasingly popular for asthma management.
- Biologics usage is increasing: Advances in the treatment of severe asthma have been dramatically achieved with the introduction of biologics such as monoclonal antibodies, by targeting specific immune responses that play a role in the disease. These therapies have been especially valuable for patients experiencing frequent exacerbations despite standard therapy. The increasing usage of biologics, which offer substantial enhancements in asthma control and quality of life, is what is driving its adoption in clinical practice and adding to market expansion.
- Combination therapies: Combination therapies are many medications in a single inhaler and can result in an even more streamlined, adherent patient, which consequently has an improvement in effectiveness overall. Combining LABAs with ICS often targets complementary elements of the therapy in asthma care. Convenience coupled with enhanced effectiveness are reasons behind their increasing acceptance by both practitioners and patients for a prescription.
- Digital Health Integration: The progress of digital health technologies, including mobile applications and wearable devices, as companions for asthma management, monitoring symptoms, tracking the use of medication, receiving reminders, and enhancing self-management have been significantly improved. For providers, digital health solutions provide valuable data on the assessment of disease control and adaptation in treatment plans. Innovation in care for asthma has been improved with better patient outcomes and engagement as a result of the integration of these technologies.
- Development of next-generation biologics: The discovery of new biological targets and pathways is opening the door to next-generation biologics. These drugs are designed to be more effective, have fewer side effects, and provide better patient outcomes. In August 2023, Areteia Therapeutics declared results from the Phase 2 EXHALE-1 study, showing the drug was capable of decreasing blood eosinophil count. Also, In July 2022, Areteia Therapeutics secured funding of USD 350 million for developing an oral asthma treatment for patients suffering from eosinophilic asthma. Success in these areas may help expand treatment options for asthma, especially for severe asthma, and open new revenue streams for pharmaceutical companies.
- Increasing focus on pediatric asthma management: Children with asthma need to be treated differently compared to adults, and hence their care requires more specific handling. There is an increasing trend toward developing pediatric-specific formulations, like reduced doses and child-friendly delivery devices, that can ensure safety and effectiveness. It creates a niche market as managing asthma in children presents specific challenges, opening the scope for companies to develop solutions that help enhance pediatric outcomes of asthma.
- Increasing Home-based Solutions for Asthma Management: This trend toward home-based care is, therefore, creating demand for such products that will enable patients to take greater control of managing their asthma on their own. Included in this are portable nebulizers, smart inhalers, and digital tools that can track symptoms and promote medicine adherence. These have been favored because they offer greater convenience and allow patients to take more control over their health care, relieving overburdened healthcare systems and promoting patient autonomy.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Asthma Therapeutics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Asthma Therapeutics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Asthma Therapeutics Market are Increased incidence of asthma, Increasing awareness and early diagnosis, and Developments in the inhalation equipment
The key future trends of the market are Biologics usage is increasing, Combination therapies, and Digital Health Integration
The leading players operating in the Asthma Therapeutics Market include AstraZeneca, GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sanofi, Cipla Inc, Intas Pharmaceuticals Ltd, Merck Sharp and Dohme Corp, F. Hoffmann-La Roche Ltd.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Asthma Therapeutics Market - By Product Type
1.3.2 Asthma Therapeutics Market - By Drug Class
1.3.3 Asthma Therapeutics Market - By Route of administration
1.3.4 Asthma Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ASTHMA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. ASTHMA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ASTHMA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. ASTHMA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. ASTHMA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ASTHMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT TYPE
7.1. OVERVIEW
7.2. PRODUCT TYPE MARKET FORECASTS AND ANALYSIS
7.3. DRY POWDER INHALERS
7.3.1. Overview
7.3.2. Dry powder inhalers Market Forecast and Analysis
7.4. METERED DOSE INHALERS
7.4.1. Overview
7.4.2. Metered dose inhalers Market Forecast and Analysis
7.5. MIST INHALERS
7.5.1. Overview
7.5.2. Mist inhalers Market Forecast and Analysis
7.6. NEBULIZER
7.6.1. Overview
7.6.2. Nebulizer Market Forecast and Analysis
8. ASTHMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANTI-INFLAMMATORY DRUGS
8.3.1. Overview
8.3.2. Anti-inflammatory drugs Market Forecast and Analysis
8.4. BRONCHODILATORS
8.4.1. Overview
8.4.2. Bronchodilators Market Forecast and Analysis
8.5. COMBINATION THERAPY
8.5.1. Overview
8.5.2. Combination therapy Market Forecast and Analysis
9. ASTHMA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
9.1. OVERVIEW
9.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
9.3. ORAL
9.3.1. Overview
9.3.2. Oral Market Forecast and Analysis
9.4. INHALED
9.4.1. Overview
9.4.2. Inhaled Market Forecast and Analysis
9.5. INTRAVENOUS
9.5.1. Overview
9.5.2. Intravenous Market Forecast and Analysis
9.6. SUBCUTANEOUS
9.6.1. Overview
9.6.2. Subcutaneous Market Forecast and Analysis
10. ASTHMA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Asthma Therapeutics Market Overview
10.1.2 North America Asthma Therapeutics Market Forecasts and Analysis
10.1.3 North America Asthma Therapeutics Market Forecasts and Analysis - By Product Type
10.1.4 North America Asthma Therapeutics Market Forecasts and Analysis - By Drug Class
10.1.5 North America Asthma Therapeutics Market Forecasts and Analysis - By Route of administration
10.1.6 North America Asthma Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Asthma Therapeutics Market
10.1.6.1.1 United States Asthma Therapeutics Market by Product Type
10.1.6.1.2 United States Asthma Therapeutics Market by Drug Class
10.1.6.1.3 United States Asthma Therapeutics Market by Route of administration
10.1.6.2 Canada Asthma Therapeutics Market
10.1.6.2.1 Canada Asthma Therapeutics Market by Product Type
10.1.6.2.2 Canada Asthma Therapeutics Market by Drug Class
10.1.6.2.3 Canada Asthma Therapeutics Market by Route of administration
10.1.6.3 Mexico Asthma Therapeutics Market
10.1.6.3.1 Mexico Asthma Therapeutics Market by Product Type
10.1.6.3.2 Mexico Asthma Therapeutics Market by Drug Class
10.1.6.3.3 Mexico Asthma Therapeutics Market by Route of administration
10.2. EUROPE
10.2.1 Europe Asthma Therapeutics Market Overview
10.2.2 Europe Asthma Therapeutics Market Forecasts and Analysis
10.2.3 Europe Asthma Therapeutics Market Forecasts and Analysis - By Product Type
10.2.4 Europe Asthma Therapeutics Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Asthma Therapeutics Market Forecasts and Analysis - By Route of administration
10.2.6 Europe Asthma Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Asthma Therapeutics Market
10.2.6.1.1 Germany Asthma Therapeutics Market by Product Type
10.2.6.1.2 Germany Asthma Therapeutics Market by Drug Class
10.2.6.1.3 Germany Asthma Therapeutics Market by Route of administration
10.2.6.2 France Asthma Therapeutics Market
10.2.6.2.1 France Asthma Therapeutics Market by Product Type
10.2.6.2.2 France Asthma Therapeutics Market by Drug Class
10.2.6.2.3 France Asthma Therapeutics Market by Route of administration
10.2.6.3 Italy Asthma Therapeutics Market
10.2.6.3.1 Italy Asthma Therapeutics Market by Product Type
10.2.6.3.2 Italy Asthma Therapeutics Market by Drug Class
10.2.6.3.3 Italy Asthma Therapeutics Market by Route of administration
10.2.6.4 Spain Asthma Therapeutics Market
10.2.6.4.1 Spain Asthma Therapeutics Market by Product Type
10.2.6.4.2 Spain Asthma Therapeutics Market by Drug Class
10.2.6.4.3 Spain Asthma Therapeutics Market by Route of administration
10.2.6.5 United Kingdom Asthma Therapeutics Market
10.2.6.5.1 United Kingdom Asthma Therapeutics Market by Product Type
10.2.6.5.2 United Kingdom Asthma Therapeutics Market by Drug Class
10.2.6.5.3 United Kingdom Asthma Therapeutics Market by Route of administration
10.2.6.6 Rest of Europe Asthma Therapeutics Market
10.2.6.6.1 Rest of Europe Asthma Therapeutics Market by Product Type
10.2.6.6.2 Rest of Europe Asthma Therapeutics Market by Drug Class
10.2.6.6.3 Rest of Europe Asthma Therapeutics Market by Route of administration
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Asthma Therapeutics Market Overview
10.3.2 Asia-Pacific Asthma Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Asthma Therapeutics Market Forecasts and Analysis - By Product Type
10.3.4 Asia-Pacific Asthma Therapeutics Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Asthma Therapeutics Market Forecasts and Analysis - By Route of administration
10.3.6 Asia-Pacific Asthma Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Asthma Therapeutics Market
10.3.6.1.1 Australia Asthma Therapeutics Market by Product Type
10.3.6.1.2 Australia Asthma Therapeutics Market by Drug Class
10.3.6.1.3 Australia Asthma Therapeutics Market by Route of administration
10.3.6.2 China Asthma Therapeutics Market
10.3.6.2.1 China Asthma Therapeutics Market by Product Type
10.3.6.2.2 China Asthma Therapeutics Market by Drug Class
10.3.6.2.3 China Asthma Therapeutics Market by Route of administration
10.3.6.3 India Asthma Therapeutics Market
10.3.6.3.1 India Asthma Therapeutics Market by Product Type
10.3.6.3.2 India Asthma Therapeutics Market by Drug Class
10.3.6.3.3 India Asthma Therapeutics Market by Route of administration
10.3.6.4 Japan Asthma Therapeutics Market
10.3.6.4.1 Japan Asthma Therapeutics Market by Product Type
10.3.6.4.2 Japan Asthma Therapeutics Market by Drug Class
10.3.6.4.3 Japan Asthma Therapeutics Market by Route of administration
10.3.6.5 South Korea Asthma Therapeutics Market
10.3.6.5.1 South Korea Asthma Therapeutics Market by Product Type
10.3.6.5.2 South Korea Asthma Therapeutics Market by Drug Class
10.3.6.5.3 South Korea Asthma Therapeutics Market by Route of administration
10.3.6.6 Rest of Asia-Pacific Asthma Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Asthma Therapeutics Market by Product Type
10.3.6.6.2 Rest of Asia-Pacific Asthma Therapeutics Market by Drug Class
10.3.6.6.3 Rest of Asia-Pacific Asthma Therapeutics Market by Route of administration
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Asthma Therapeutics Market Overview
10.4.2 Middle East and Africa Asthma Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Asthma Therapeutics Market Forecasts and Analysis - By Product Type
10.4.4 Middle East and Africa Asthma Therapeutics Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Asthma Therapeutics Market Forecasts and Analysis - By Route of administration
10.4.6 Middle East and Africa Asthma Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Asthma Therapeutics Market
10.4.6.1.1 South Africa Asthma Therapeutics Market by Product Type
10.4.6.1.2 South Africa Asthma Therapeutics Market by Drug Class
10.4.6.1.3 South Africa Asthma Therapeutics Market by Route of administration
10.4.6.2 Saudi Arabia Asthma Therapeutics Market
10.4.6.2.1 Saudi Arabia Asthma Therapeutics Market by Product Type
10.4.6.2.2 Saudi Arabia Asthma Therapeutics Market by Drug Class
10.4.6.2.3 Saudi Arabia Asthma Therapeutics Market by Route of administration
10.4.6.3 U.A.E Asthma Therapeutics Market
10.4.6.3.1 U.A.E Asthma Therapeutics Market by Product Type
10.4.6.3.2 U.A.E Asthma Therapeutics Market by Drug Class
10.4.6.3.3 U.A.E Asthma Therapeutics Market by Route of administration
10.4.6.4 Rest of Middle East and Africa Asthma Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Asthma Therapeutics Market by Product Type
10.4.6.4.2 Rest of Middle East and Africa Asthma Therapeutics Market by Drug Class
10.4.6.4.3 Rest of Middle East and Africa Asthma Therapeutics Market by Route of administration
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Asthma Therapeutics Market Overview
10.5.2 South and Central America Asthma Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Asthma Therapeutics Market Forecasts and Analysis - By Product Type
10.5.4 South and Central America Asthma Therapeutics Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Asthma Therapeutics Market Forecasts and Analysis - By Route of administration
10.5.6 South and Central America Asthma Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Asthma Therapeutics Market
10.5.6.1.1 Brazil Asthma Therapeutics Market by Product Type
10.5.6.1.2 Brazil Asthma Therapeutics Market by Drug Class
10.5.6.1.3 Brazil Asthma Therapeutics Market by Route of administration
10.5.6.2 Argentina Asthma Therapeutics Market
10.5.6.2.1 Argentina Asthma Therapeutics Market by Product Type
10.5.6.2.2 Argentina Asthma Therapeutics Market by Drug Class
10.5.6.2.3 Argentina Asthma Therapeutics Market by Route of administration
10.5.6.3 Rest of South and Central America Asthma Therapeutics Market
10.5.6.3.1 Rest of South and Central America Asthma Therapeutics Market by Product Type
10.5.6.3.2 Rest of South and Central America Asthma Therapeutics Market by Drug Class
10.5.6.3.3 Rest of South and Central America Asthma Therapeutics Market by Route of administration
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ASTHMA THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. KONINKLIJKE PHILIPS N.V
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ASTRAZENECA
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. GLAXOSMITHKLINE PLC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. SANOFI
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. CIPLA INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. INTAS PHARMACEUTICALS LTD
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK SHARP AND DOHME CORP
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. F. HOFFMANN-LA ROCHE LTD
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
- AstraZeneca
- GlaxoSmithKline Plc.
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Sanofi
- Cipla Inc
- Intas Pharmaceuticals Ltd
- Merck Sharp and Dohme Corp
- F. Hoffmann-La Roche Ltd
- Dr Reddy's Laboratories Ltd
- Sunovion Pharmaceuticals, Inc
- Abbott
- Glenmark
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For